AmSurg stock rated at ‘buy’

Analysts from Cantor Fitzgerald have rated AmSurg stock at “buy,” according to an Analyst Ratings report.

Advertisement

Cantor Fitzgerald set the company’s shares at a price target of $67. AmSurg has a market cap of $2.98 billion.

More articles on transactions and valuation issues:
How much does it cost to build an outpatient surgery center?
SCA closes secondary public offering of common stock
AmSurg acquires Halifax Anesthesiology Associates

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.